Serum cystatin C levels of prostate cancer and benign prostatic hyperplasia patients

Benign prostate hyperplasia (BHP) is the most common disease which is diagnosed and can be cured and it is existing in the %60 of the men among the 60 years-old. It can be only possible to cure the prostate cancer with early diagnosis. For this reason, it has been studied whether a variety of molecules, including biochemical markers, can be a tumour marker for prostate cancer in a number of studies or not. For that purpose, we have aimed to search the usability of Cystatin C to distinguish of these two clinical table. We showed that Cystatin C is stabile in BPH case while it increases at prostate cancer cases. It has been found that the level serum Cystatin C in the gathered samples is 1051±23 ng/ml in control group, 1023±22 ng/ml in BPH group, and 1146±38 ng/ml in prostate cancer group. Limit value of Cystatin C has been found as 1104 ng/ml at diagnosing prostate cancer. Moreover, while the serum PSA level of the samples in our study is found to be higher in the BPH (8,60±1,70 ng/ml) and prostate cancer cases (53,53±14,93 ng/ml) than the control group (1,92±0,35 ng/ml) (p<0,05), the PSA serum of the prostate cancer cases is found to be higher than the BPH group (p<0,05). While the level of fPSA serum is higher in the BPH (2,20±0,60 ng/ml) and prostate cancer cases (2,50±0,30 ng/ml) than the control group (0,50±0,10 ng/ml) (p<0,05), the serum fPSA of the prostate cancer cases is found to be higher than the BPH group (p<0,05). While the levels of fPSA/PSA are lower in prostate cancer cases (11,60±1,60) than the control group (31,60±4,10) (p<0,05), fPSA/PSA of the prostate cancer is found to be lower then the BPH groups (27,50±3,90) (p<0,05). More clinical studies are need to use Cystatin C for diagnosing and post- treatment. Keywords : Benign prostate hyperplasia, Prostate cancer, Cystatin C, Prostate specific antigen.